drugset / Trial / NCT02022501
A Phase I/II Safety Study of DE-120 Injectable Solution for Age-related Macular Degeneration
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety, tolerability, bioactivity and pharmacokinetics of three concentrations of DE-120 after a single intravitreal injection in subjects with late stage exudative age-related macular degeneration.
Timeline
- Start
- 2014-01
- Primary completion
- 2016-04-21
- Completion
- 2016-04-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DE-120 | Unknown | 0.02 ml | Intravitreal |